Table 1. Untreated Fgfr3^ach/+ mice displayed an elevated inflammatory baseline prevented by sFGFR3 treatment.

	ND			HFD
	WT	Fgfr3 ach/+		WT	Fgfr3 ach/+
markers (n)	vehicle	vehicle	2.5 mg/kg sFGFR3	vehicle	vehicle	2.5 mg/kg sFGFR3
Pro-inflammatory (14)	+	++	+	+	++	+
Obesity (15)	++	+++	+	++	+++	++
Insulin pathway (7)	++	++	++	++	+++	++
FGF (2)	+	+	-	-	++	-

Pro-inflammatory, obesity, insulin pathway and FGF circulating adipokines expression performed into vehicle-treated WT and Fgfr3^ach/+ mice and sFGFR3 treated Fgfr3^ach/+ after 10 weeks of ND or HFD challenge. ‘-’ = <2 arbitrary units (A.U.), ‘+’ = 10–30 A.U., ‘++’ = 30–100 A.U., ‘+++’ >100 A.U.